Meeting Program

The meeting program begins on Thursday, January 30 at 12:00 and ends on Saturday, February 1 at 16:45. 
Please visit this page regularly for the most up to date program. 

Day 1, Thursday, January 30

12:00 - 12:15 Opening Ceremony

  • Opening & Welcome
    H Einsele & C Chabannon (Chairs of the Scientific Program Committee)
  • About EHA/EBMT and their activities
    J Gribben (President EHA) & N Kröger (President EBMT)

12:15 - 12:45 Keynote Lecture

Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee)

  • Informed design of engineered T cell therapies for cancer
    S Riddell (United States)

12:45 - 14:15 Indications for CAR T Cell therapy

Chairs: J Gribben (President EHA) & N Kröger (President EBMT)

  • Acute leukemia
    A Nagler (Israel)
  • Multiple myeloma
    H Einsele (Germany)
  • Lymphoma
    C Thieblemont (France)

14:15 - 15:15 Improving the efficacy and safety profile

Chairs: M Hudecek (Germany) & C MacKall (United States)

  • Targeted genomic insertion
    D Busch (Germany)
  • Virus-free gene transfer & genome editing
    Z Ivics (Germany)
  • In vivo transduction
    Speaker to be announced

15:15 - 15:45 Coffee break & Industry theater session

15:45 - 16:15 Keynote lecture

Chairs: A Baruchel (France) & second Chair to be confirmed

  • Engineering next generation CAR T cells to overcome resistance 
    C MacKall (United States)

16:15 - 17:15 CAR T in pediatrics

Chairs:  A Baruchel (France) & second Chair to be confirmed

  • Post transplant relapse-Second SCT or CAR T-cells
    P Bader (Germany)
  • Neuroblastoma
    F Locatelli (Italy) 
  • Bispecific CAR T Cells
    P Amrolia (United Kingdom)

17:15 - 17:45  Keynote Lecture

Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee)

  • M Pule (United Kingdom)

17:45 - 18:45 Best Abstracts & Flash Talks - Part I

Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee)

19:00 - 19:45 Satellite Symposium

19:30 - 20:30 Welcome reception & poster session

Day 2, Friday, January 31

08:30 - 09:30 Latest clinical & pre-clinical pipeline Part I

Chairs: J Kuball (the Netherlands) & second Chair to be confirmed

  • ROR1 in CLL / lymphoma / breast cancer
    D Maloney (United States)
  • Novel CAR targets for MM
    N Hosen (Japan) 
  • CD123 for AML and CNS tumors
    S Forman (United States)

09:30 - 10:00 Keynote Lecture

Chairs: J Kuball (the Netherlands) & second Chair to be confirmed

  • Updates in CAR T cell therapy
    C June (United States)

10:00 - 11:00 Latest clinical & pre-clinical pipeline Part II

Chairs: J Kuball (the Netherlands) & second Chair to be confirmed

  • CD30 / TSCM
    J Briones (ES)
  • A Künkele (DE)
  • iPS CARs
    M Themeli (the Netherlands)

11:00 - 11:30 Coffee break & Industry theater session

11:30 - 12:30 Best Abstracts & Flash Talks - Part II

Chairs: M Hudecek (Germany) & A Urbano-Ispizua (Spain)

12:30 - 13:00 Keynote lecture

Chairs: M Hudecek (Germany) & A Urbano-Ispizua (Spain)

  • Current CAR T trial activities in China
    JX Wang (China)

13:00 - 14:30 Lunch break

13:45 - 14:30 Satellite Symposium

14:30 - 15:00 Keynote lecture

Chairs: I Yakoub-Agha (France) & D Büsch (Germany)

  • M Sadelain (United States)

15:00 - 16:00 CAR effector cells

Chairs: I Yakoub-Agha (France) & D Büsch (Germany)

  • CAR expressing NK cells for cancer retargeting
    K Rezvani (United States)
  • Allogeneic CAR T cells
    W Qasim (United Kingdom)
  • CAR-NK cells as off-the-shelf therapeutics bridging innate and adaptive immunity
    W Wels (Germany)

16:00 - 17:00 Optimizing CAR T treatment

Chairs: M Mohty (France) & second Chair to be confirmed

  • Microbiome
    M van den Brink (United States)
  • Visualizing CAR T-cells at work
    J Huppa (Austria)
  • Improving CART-cells in solid tumors
    S Guedan (Spain)

17:00 - 17:30 Coffee break & Industry theater session

17:30 - 19:00 CAR T regulatory session

  • EMA
    M Schüssler-Lenz (Germany)
  • U Jäger (Austria)
  • Registry
    C Chabannon (France)
  • Patient Perspective
    B Verhoeven (the Netherlands)

19:00 - 19:45 Satellite Symposium

Day 3, Saturday, February 1

08:30 - 09:45 European Grants/Projects

  • CARAMBA (H2020, SLAMF7 CAR-T)
    M Hudecek (Germany)
  • EURE-CART (H2020, CD44v6 CAR-T)
    F Ciceri (Italy)
  • CARAT (H2020; CAR-T manufacturing)
    M Assenmaher (Germany)
  • imSAVAR
    U Köhl (DE)

08:30 - 09:45 Nurses session - Patient care - Part I

  • Introduction & Welcome
    J Murray & E Aerts
  • The science of IEC and what is new
    E Vickers (United Kingdom)
  • Solid Tumours and IEC
    Speaker to be announced
  • Clinical Trial updates
    I Yakoub-Agha (France)

08:30 - 09:45 Data managers session - Part I

  • Content of the Advanced Cellular Therapies form
    C Chabannon (France)
  • The advanced cellular therapies form in MACRO - data entry overview
    L Stolarczyk (United Kingdom)
  • CAR T data collection – CIBMTR experience
    M Pasquini (United States)

09:45 - 10:15 Coffee break & Industry theater session

10:15 - 12:00 Management of side effects (Round table discussion)

  • A Baruchel (France)
  • MJ Kersten (the Netherlands)
  • I Yakoub-Agha (France)
  • Speaker to be announced

10:15 - 12:00 Nurses session - Patient care - Part II

  • Apheresis in adults and pediatrics
    D Hutt (Israel)
  • Real world experience of commercial IEC
    JM Cano Ruiz (ES)
  • Managing expectations
    M Kenyon (United Kingdom)
  • Psychology and CAR-T
    Speaker to be announced

10:15 - 12:00 Data managers session - Part II

  • Follow-up of CAR-T Cell treatments. The EMA Registry Initiative
    J Kuball (the Netherlands)
  • Follow-up of gene therapies used to treat inborn errors
    Speaker to be announced
  • PASS studies
    A van Biezen (the Netherlands)
  • Toxicities in CAR-T therapy - recognition and management
    R Benjamin (United Kingdom)

12:00 - 13:00 Lunch Break

12:15 - 13:00 Satellite Symposium

13:00 - 14:30 Implementation of CAR-T Cells in the real world (Round table discussion)

Chairs:  C Rössig (Germany) & second Chair to be confirmed

  • S Mielke (Sweden)
  • G Salles (France)
  • M Mohty (France)
  • M Pasquini (United States)

13:00 - 14:30 Physicians session - Manufacutring of CAR T Cell in an Academic setting

Chairs:  U Köhl (Germany) & second Chair to be confirmed

13:00 - 14:30 Nurses session - Patient care - Part III

  • Nursing guidelines and Network for IEC
    R Ellard (United Kingdom)
  • Nurse training program
    R Clout (United Kingdom)
  • The patient experience
    Speaker to be announced
  • Relapse post CAR-T options
    C Bompoint (France)

14:30 - 15:00 Coffee break & Industry theater session

15:00 - 16:30 Manufacturing of CAR T cell and supply chain management

15:00 - 16:30 Nurses session - Patient care - Part IV

The final session will offer the opportunity for our participants to attend a special Panel Discussion hosted by 5 International experts in the field of CAR-T therapy. Questions and practice challenges from throughout the day will be discussed and debated.  We want to encourage the involvement and contribution of our participants to create stimulating and interesting discussions and generate new knowledge and approaches to Nursing care in the CAR-T setting.

Following the Panel Discussion we will then break out onto 5 ‘meet the expert’ tables where participants will explore a specific theme, and bring their own questions and topics to discuss in a more intimate environment. Participants will rotate from table to table every 10 minutes.

16:30 - 16:45 Closing Remarks

  • H Einsele & C Chabannon (Chairs of the Scientific Program Committee)